Earlier this week the Centers for Disease Control and Prevention (CDC) expressed their preference for Pfizer-BioNTech and Moderna’s mRNA COVID-19 vaccines over Johnson & Johnson’s jab.
Naomi Wolf knows why. The NIAID doesn’t hold the patents of the J&J vaccine.
Naomi Wolf: Moderna and Pfizer have been trying to sideline Johnson&Johnson partly because as Rob Kennedy will tell you, the stakeholders at the NIAID don’t have a patent on and don’t make money on the J&J vaccine. So they want it out of the marketplace. It’s not the first time they’ve said, “Oh that bad J&J vaccine.” …Anyone who’s looked at VAERS and saw the thousands of blood clots and thrombotic events, strokes, thrombotic events, for Pfizer and Moderna as well as J&J, knows this is absolute ludicrisy.